Biologicals in the treatment of psoriasis.

Article Details

Citation
Copy to clipboard

Boker A, Kimball AB, Rolz-Cruz G

Biologicals in the treatment of psoriasis.

Curr Opin Investig Drugs. 2007 Nov;8(11):939-46.

PubMed ID
17979028 [ View in PubMed
]
Abstract

Psoriasis is a chronic inflammatory skin disorder that can cause substantial disability. The recognition of psoriasis as an immunologically mediated disease led to the development of agents that specifically target key steps in the pathological process. This review focuses on these biological agents, and presents results from phase II and III clinical trials together with the safety profile and approved indications for alefacept, efalizumab, etanercept, infliximab and adalimumab. Preliminary safety and efficacy data for the newer therapeutic agents, such as CNTO-1275 and ABT-874, are also described.

DrugBank Data that Cites this Article

Drugs